An open-label, randomized phase III trial of gemcitabine and carboplatin (GC) followed by Epstein-Barr virus-specific autologous cytotoxic t lymphocytes (EBV-CTLs) versus GC as front-line therapy for patients (pts) with advanced nasopharyngeal carcinoma (NPC).

Han-Chong Toh,Josemund Menezes

An open-label, randomized phase III trial of gemcitabine and carboplatin (GC) followed by Epstein-Barr virus-specific autologous cytotoxic t lymphocytes (EBV-CTLs) versus GC as front-line therapy for patients (pts) with advanced nasopharyngeal carcinoma (NPC).

2018

Han-Chong Toh
Josemund Menezes

6082Background: Median overall survival (OS) and prognosis in patients with advanced EBV-positive NPC remain poor and treatment options are limited. In a small phase II trial (38 Asian pts), EBV-CT...

Keywords:

Carboplatin
Pathology
Nasopharyngeal carcinoma
Epstein–Barr virus
Cytotoxic T cell
Gemcitabine
Cancer research
Medicine
open label
Front line
Oncology
Internal medicine
treatment options

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations